NYSE:NVS - Novartis Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$83.04 +0.85 (+1.03 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$83.04
Today's Range$82.75 - $83.22
52-Week Range$72.30 - $94.19
Volume1.36 million shs
Average Volume1.75 million shs
Market Capitalization$190.26 billion
P/E Ratio17.26
Dividend Yield2.33%
Beta0.82
Novartis logoNovartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; and PEAR Therapeutics. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVS
CUSIPN/A
Phone41-61-324-1111

Debt

Debt-to-Equity Ratio0.30
Current Ratio1.15
Quick Ratio0.89

Price-To-Earnings

Trailing P/E Ratio17.26
Forward P/E Ratio16.41
P/E Growth1.82

Sales & Book Value

Annual Sales$49.11 billion
Price / Sales3.92
Cash Flow$7.6253 per share
Price / Cash10.89
Book Value$32.03 per share
Price / Book2.59

Profitability

EPS (Most Recent Fiscal Year)$4.81
Net Income$7.70 billion
Net Margins27.06%
Return on Equity16.05%
Return on Assets8.67%

Miscellaneous

Employees121,597
Outstanding Shares2,317,460,000
Market Cap$190.26 billion

Novartis (NYSE:NVS) Frequently Asked Questions

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How will Novartis' stock buyback program work?

Novartis announced that its Board of Directors has initiated a share repurchase plan on Saturday, April 8th 2017, which permits the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 2.9% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board believes its shares are undervalued.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) issued its quarterly earnings data on Wednesday, July, 18th. The company reported $1.29 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.27 by $0.02. The business had revenue of $13.16 billion for the quarter, compared to analyst estimates of $12.93 billion. Novartis had a return on equity of 16.05% and a net margin of 27.06%. The firm's revenue for the quarter was up 7.5% on a year-over-year basis. During the same period last year, the business posted $1.22 earnings per share. View Novartis' Earnings History.

When is Novartis' next earnings date?

Novartis is scheduled to release their next quarterly earnings announcement on Tuesday, October, 23rd 2018. View Earnings Estimates for Novartis.

What price target have analysts set for NVS?

10 equities research analysts have issued 12 month target prices for Novartis' shares. Their forecasts range from $91.00 to $91.00. On average, they anticipate Novartis' share price to reach $91.00 in the next year. This suggests a possible upside of 9.6% from the stock's current price. View Analyst Price Targets for Novartis.

What is the consensus analysts' recommendation for Novartis?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 1 sell rating, 8 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.

Are investors shorting Novartis?

Novartis saw a increase in short interest in July. As of July 13th, there was short interest totalling 1,796,542 shares, an increase of 77.0% from the June 29th total of 1,014,840 shares. Based on an average daily volume of 1,897,726 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.1% of the company's stock are short sold. View Novartis' Current Options Chain.

Who are some of Novartis' key competitors?

Who are Novartis' key executives?

Novartis' management team includes the folowing people:
  • Dr. Vasant Narasimhan, Chief Exec. Officer (Age 42)
  • Mr. Harry Kirsch, Chief Financial Officer (Age 53)
  • Mr. Steven Baert, Head of HR (Age 44)
  • Mr. Richard Francis, Chief Exec. Officer of Sandoz (Age 50)
  • Dr. James E. Bradner M.D., Pres of Novartis Institutes for Biomedical Research (Age 46)

Has Novartis been receiving favorable news coverage?

Media stories about NVS stock have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Novartis earned a news and rumor sentiment score of 0.10 on Accern's scale. They also assigned media stories about the company an impact score of 46.46 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for Novartis.

Who are Novartis' major shareholders?

Novartis' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Wells Fargo & Company MN (0.33%), Fisher Asset Management LLC (0.32%), Bank of America Corp DE (0.29%), Boston Partners (0.24%), Parnassus Investments CA (0.20%) and Charles Schwab Investment Advisory Inc. (0.17%). Company insiders that own Novartis stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis.

Which institutional investors are selling Novartis stock?

NVS stock was sold by a variety of institutional investors in the last quarter, including Parnassus Investments CA, United Services Automobile Association, Douglass Winthrop Advisors LLC, Bank of New York Mellon Corp, Saturna Capital CORP, FMR LLC, South Texas Money Management Ltd. and Delek Group Ltd.. View Insider Buying and Selling for Novartis.

Which institutional investors are buying Novartis stock?

NVS stock was acquired by a variety of institutional investors in the last quarter, including Charles Schwab Investment Advisory Inc., Boston Partners, Renaissance Technologies LLC, Fiera Capital Corp, Janus Henderson Group PLC, Fisher Asset Management LLC, Cornerstone Wealth Management LLC and Fort Washington Investment Advisors Inc. OH. Company insiders that have bought Novartis stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis.

How do I buy shares of Novartis?

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $83.04.

How big of a company is Novartis?

Novartis has a market capitalization of $190.26 billion and generates $49.11 billion in revenue each year. The company earns $7.70 billion in net income (profit) each year or $4.81 on an earnings per share basis. Novartis employs 121,597 workers across the globe.

How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]


MarketBeat Community Rating for Novartis (NYSE NVS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  374 (Vote Outperform)
Underperform Votes:  442 (Vote Underperform)
Total Votes:  816
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2018 by MarketBeat.com Staff

Featured Article: Technical Analysis

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.